Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 24.2%, from $318.00M to $241.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a 122.7% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $167.25M | $167.25M | $167.25M | $0.00 | $0.00 | $1.13B | $49.00M | $2.54B | $246.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $318.00M | -$16.78B | -$1.00M | $0.00 | $241.00M |
| QoQ Change | — | +0.0% | +0.0% | -100.0% | — | — | -95.7% | >999% | -90.3% | -100.0% | — | — | — | — | — | — | <-999% | +100.0% | +100.0% | — |
| YoY Change | — | — | — | — | -100.0% | +573.8% | -70.7% | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | — | — | -24.2% |